These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 28078599

  • 1. Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.
    Sanfilippo CM, Allaire CM, DeCory HH.
    Drugs R D; 2017 Mar; 17(1):167-175. PubMed ID: 28078599
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
    Comstock TL, Paterno MR, Usner DW, Pichichero ME.
    Paediatr Drugs; 2010 Apr 01; 12(2):105-12. PubMed ID: 20218747
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB, Protzko EE, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock TL, Usner DW.
    Ophthalmology; 2009 Sep 01; 116(9):1615-1623.e1. PubMed ID: 19643483
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Besifloxacin ophthalmic suspension 0.6%.
    Carter NJ, Scott LJ.
    Drugs; 2010 Sep 01; 70(1):83-97. PubMed ID: 20030427
    [Abstract] [Full Text] [Related]

  • 11. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.
    Comstock TL, Paterno MR, Decory HH, Usner DW.
    Clin Drug Investig; 2010 Sep 01; 30(10):675-85. PubMed ID: 20629472
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The role of besifloxacin in the treatment of bacterial conjunctivitis.
    Mahvan TD, Hornecker JR, Buckley WA, Clark S.
    Ann Pharmacother; 2014 May 01; 48(5):616-25. PubMed ID: 24566460
    [Abstract] [Full Text] [Related]

  • 14. Besifloxacin ophthalmic suspension for bacterial conjunctivitis.
    Nafziger AN, Bertino JS.
    Drugs Today (Barc); 2009 Aug 01; 45(8):577-88. PubMed ID: 19927224
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.
    Malhotra R, Ackerman S, Gearinger LS, Morris TW, Allaire C.
    Drugs R D; 2013 Dec 01; 13(4):243-52. PubMed ID: 24142473
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
    Heller W, Cruz M, Bhagat YR, De Leon JM, Felix C, Villanueva L, Hollander DA, Jensen H.
    J Ocul Pharmacol Ther; 2014 Dec 01; 30(10):815-22. PubMed ID: 25244402
    [Abstract] [Full Text] [Related]

  • 19. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
    Abelson MB, Heller W, Shapiro AM, Si E, Hsu P, Bowman LM, AzaSite Clinical Study Group.
    Am J Ophthalmol; 2008 Jun 01; 145(6):959-65. PubMed ID: 18374301
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.